756521-08-1

Usage

Uses

Used in Chemical Synthesis:
3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine is used as a chemical intermediate for the synthesis of various complex organic molecules. Its unique structure, which includes halogens and nitro groups, makes it a valuable building block in the preparation of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Research and Development:
In the field of organic chemistry, 3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine serves as a research compound for studying the reactivity and properties of halogenated aromatic compounds. Its potential applications in the development of new chemical reactions and methodologies are being explored, contributing to the advancement of synthetic chemistry.
Used in Material Science:
3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine is used as a component in the development of new materials with specific properties, such as electronic or optical characteristics. Its incorporation into polymers or other materials can lead to the creation of novel materials with potential applications in various industries, including electronics, photonics, and energy storage.

Upstream product

• 15128-82-2 3-hydroxy-2-nitropyridine 
• 756520-66-8 1-(2,6-dichloro-3-fluorophenyl)ethanol 
• 1229457-91-3 1-(2,6-dichloro-3-fluorophenyl)ethyl methanesulfonate 
• 290835-85-7 2',6'-dichloro-3'-fluoroacetophenone 

Downstream Products

• 756520-67-9 (±)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine 
• 1421270-71-4 (±)-tert-butyl 6-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptane-2-carboxylate 
• 1421270-66-7 C₂₂H₂₂Cl₂FN₅O*CH₂O₂ 
• 877397-71-2 (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethyoxyl)-2-aminopyridine 
• 877401-42-8 tert-butyl 4-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 877400-66-3 (+/-)-PF023401066 
• 877399-08-1 (±)-3-(1-(2,6-dichloro-3-fluoropheny)ethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine 
• 1331786-34-5 (±)-bis(Boc)-3-(1-(2,6-dichloro-3-fluoropheny)ethoxy)-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridin-2-amine 

Relevant academic research and scientific papers

Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants

Despite the initial benefit demonstrated in clinical setting with ALK inhibitors, the challenging resistant mutants (F1174L, L1196M and G1202R) invariably developed. In this work, a series of 2-aminopyridine derivatives were designed and synthesized by C-5 position incorporation of a 2-pyridone moiety and bioisosteric replacement of the C-3 position linkers. Optimization of the 2-aminopyridine derivatives led to the identification of hit 18d displaying a significant growth inhibition against a variety of ALK-addicted cancer cells. Especially in the case of ALK-positive Karpas-299 cell, 18d exhibited excellent anti-proliferative potency with an IC50 value of about 40 nM. Moreover, 18d demonstrated encouraging activities against wild-type ALK (19 nM), ROS1 (2.3 nM) as well as challenging crizotinib-resistant ALKL1196M and ALKG1202R mutants with IC50 values of 45 nM and 22 nM, respectively. Additionally flow cytometric analysis indicates that 18d inhibited Karpas-299 cell viability via G1 phase arrest. Taken together, this work provided a promising ALK inhibitor to circumvent the clinical crizotinib-resistant mutants.

Method for preparing Crizotinib chiral intermediate

The invention relates to a method for preparing a Crizotinib chiral intermediate, which belongs to the field of medicine synthesis. The preparation method of the intermediate (1) is characterized in that chiral organic acidity is taken as a resolving agen

Inhibitors of nedd8-activating enzyme

The invention relates to an administration unit comprising crystalline form I of {(1 S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (I-216) hydrochloride salt and to a packaging comprising the administration unit according to the invention.

AMINO HETEROARYL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention refers to aminoheteroaryl compounds of the following formula (I) as well as the preparation method and use thereof, wherein R1 and R3 are defined in the Description in details. The aminoheteroaryl compounds of t

Aminoheteroaryl compounds and preparation method and use thereof

The present invention refers to aminoheteroaryl compounds of the following formula (I) as well as the preparation method and use thereof, wherein R1 and R3 are defined in the Description in details. The aminoheteroaryl compounds of t

SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS

The present invention relates to spirocyclic compounds of formula I, namely spirocyclic (1H-pyrazol-4-yl)-3-(1-(2,6-dichloro-3-fiuorophenyl) ethoxy)pyridin-2-amines having protein kinase inhibitory activity, and methods of synthesizing and using such compounds. Preferred compounds are c-Met and/or ALK inhibitors useful for the treatment of abnormal cell growth, such as cancers

PYRIDINE COMPOUNDS AS INHIBITORS OF KINASE

Disclosed are pyridines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.

CRIZOTINIB FOR USE IN THE TREATMENT OF CANCER

The present invention relates to the use of ROS kinase inhibitors for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ROS by administration of crizotinib.

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

Because of the critical roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncology targets for therapeutic intervention. The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design. A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3. In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE). Further optimization of the lead series generated the clinical candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.